For Release: **Immediately**

Contact: Media –
Aidan Gormley, Director, Global Communications and Branding 216/896-3258
aidan.gormley@parker.com

Stock Symbol: PH - NYSE

Parker Receives Expanded FDA Clearance for Indego® Exoskeleton for Personal and Clinical Use

- New indication for use at T3 injury level and below for personal use is broadest available for exoskeletons in the United States and expands the population of spinal cord injury patients that can use the device.

CLEVELAND, September 25, 2017 – The Human Motion Business Unit of Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for use (IFU) for the Indego® exoskeleton, a device that enables individuals with paraplegia to stand and walk. Indego was previously cleared by the FDA in February 2016 for use by individuals with spinal cord injury levels of T4 and lower in rehabilitation facilities, and with T7 and lower injury levels for use in home and community settings. The new indication for use greatly expands the population that can use the device to include spinal cord injury patients at C7 and lower injury levels in rehabilitation facilities and T3 and lower injury levels for use in home and community settings.

“The new clearance by the FDA provides the Indego exoskeleton with the broadest IFU of any commercial exoskeleton available in the United States,” said Achilleas Dorotheou, head of the Human Motion and Control business unit for Parker. “Indego is now available to a significantly larger segment of the spinal cord injury population and is an option for personal use among more than 40% of spinal cord injured Americans. We credit several VA medical directors with urging us to pursue this expanded clearance and it is likely that some of the 40,000 spinal cord injured veterans served by the VA system will be among the immediate beneficiaries.”

The clearance of an expanded IFU for Indego comes after the successful implementation of an FDA 522 Postmarket Surveillance Study, along with two ongoing clinical trials designed to provide evidence supporting future submissions for FDA clearance for additional software suites and functionalities that

will further enhance Indego's value in rehabilitation centers. Parker is also developing an array of new powered and programmable variants of Indego to be submitted for regulatory approval over the next several years addressing other partial or moderate impairments such as multiple sclerosis, stroke, and musculoskeletal weakness.

Since the commercial launch of Indego in May 2016, systems have been sold for commercial use at leading clinical rehabilitation centers and for use in homes and communities throughout the United States and Europe. During that time, Parker has performed extensive work to support the clinical, health and economic benefits of regular use of the Indego system, building the evidence required to convince insurers to cover the device, which would make this revolutionary technology more widely accessible.

Indego is a state-of-the-art rehabilitation and assistive technology designed to improve patient mobility and independence while offering clinicians a meaningful therapy tool. Indego has received FDA Clearance and CE Mark, allowing it to be sold commercially in the U.S. and Europe. Indego has also earned a UL Mark which was obtained through extensive testing to certify the high standards of the Indego system design, function and safety. To learn more about Indego visit www.indego.com

Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.